Merck, Schering-Plough metabolic news

Data vendor Verispan LLC estimated that total U.S. prescriptions for Vytorin ezetimibe/simvastatin fell (10%) to 359,659 in the week ended Jan. 18 from 397,533 the previous week, after Merck and Schering-Plough reported the drug missed the primary endpoint in the Phase III ENHANCE trial to treat heterozygous familial hypercholesterolemia (HeFH). ...